Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
ApexOnco Front Page
Recent articles
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Genmab acquires the Dutch biotech for $8bn.
BNT329 enters the clinic, as do four other new ADCs.
Four more failed tiragolumab trials, including Imbrave-152, will feature.
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
